Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,697 total articles
Toyota (TM) checks the boxes for a defensive long: attractive valuation (12.6x P/E), a 2.36% yield, improving technical momentum, and a large, diversified business that still generates industry-leading margins. Enter around current levels with a tight structural stop under the 50-day average and a target that prices in moderate re-rating and contin…
Lyft is oversold after a revenue miss but is generating strong adjusted EBITDA and free cash flow. At a market cap of roughly $5.7B and free cash flow north of $1.0B, the setup favors a tactical long while bookings and margin expansion reassert themselves. Technicals are stretched, which creates a defined risk-reward for a swing trade.
Incyte shares pulled back after guidance commentary and a mixed readout cycle. The drop looks driven by sentiment and short-volume pressure rather than a lasting hit to profitability or balance sheet strength. With a market cap near $19.5B, a healthy free cash flow stream and negligible debt, Incyte is a candidate for a tactical long on a mean-reve…
Palantir is selling an OS for mission-critical autonomy and operational AI. Q4 2025 results and large commercial deal flow show accelerating adoption; trading near $135 after a pullback creates a tradeable long with defined risk. The thesis: the market re-rates as Palantir converts performance obligations into recurring enterprise deployments, but …
Red Cat (RCAT) has shifted from development to production: Q4 revenue of $24-26.5M and a $35M production contract give the stock a fresh fundamental story. With an upcoming Innovation Day likely to spotlight new products and production scale, we outline a swing trade to capture an event-driven re-rate while controlling downside with a defined stop.
Hochschild Mining (HCHDF) looks like a workable long for metal bulls. Price is above key short-term moving averages, RSI is constructive, and short interest has collapsed since late 2025. Given the OTC listing and limited public metrics, this is a trading idea focused on momentum and position sizing rather than a full fundamental re-rate.
Hims & Hers (HIMS) collapsed after a legal and regulatory attack on its copycat GLP-1 offering. The pullback has left the stock oversold, valuation depressed relative to near-term prospects, and technicals signaling an extreme short-term bottom. This is a tactical long idea: enter $17.00, stop $15.50, target $22.00, horizon mid term (45 trading day…
SSR Mining is producing more metal, holding AISC roughly flat, and benefiting from gold north of $3,300/oz. Valuation metrics (P/E ~24.6, EV/EBITDA ~11.6) and positive cash flow support a buy-to-swing trade. Entry $26.25, stop $24.00, target $31.00 with a mid-term horizon.
Micron (MU) has skyrocketed from its 2025 trough, yet a $440B market cap and mid-30s P/E still look defendable given accelerating revenue, expanding margins, and signed HBM supply into 2026. This trade idea lays out a mid-term swing long with an entry at current levels, a clear stop, and a target that captures further cyclical upside while respecti…
AllianceBernstein (AB) is a practical swing trade for investors looking to play a potential market-driven pickup in asset-gathering and fee income in 2026. The stock sits below its 10- and 20-day moving averages, offering a measured entry around $39.75, a clear stop at $36.50 and a target at $45.00 that captures re-rating toward recent highs and im…
Columbus McKinnon (CMCO) is showing technical strength and a clearer fundamental runway: stable cash flow, modest leverage, and exposure to growing material-handling markets. This trade idea lays out a mid-term swing entry, specific stop and target, catalysts to watch, and the risks that would invalidate the setup.
Coeur Mining has moved from survival-mode volatility to a structurally stronger producer with diversified North American assets, improving cash flow and a low-leverage balance sheet. At $22.50, the stock offers an asymmetric risk/reward backed by solid free cash flow, an active M&A pipeline and leverage to a still-tight silver market. This trade id…
Planet Labs has consolidated government contracts, a growing backlog and improving profitability metrics that, in our view, make it the preferred long-term exposure to commercial earth observation versus BlackSky. This trade idea outlines a long trade in Planet Labs with an entry at $21.50, a $30 target and an $18 stop, and explains the fundamental…
BP's decision to suspend buybacks to pay down roughly $22.2 billion of net debt and reallocate cash toward core growth (EV charging, low-carbon fuels) is a pragmatic reset that should reduce headline risk, preserve the 5.2% yield and create optionality for a reactivated buyback program later in 2026. Technicals and a modest valuation - PB ~1.79, ma…
Pembina (PBA) is a cash-generative midstream operator trading near its all-time high after a run. The stock still offers an attractive 4.7% yield, reasonable valuation (PE ~21.6, PB ~2.3) and pipeline-backed growth via recent M&A and an LNG FID. We lay out an actionable long trade for income-minded investors aiming for high-single-digit upside whil…
Spero Therapeutics (SPRO) is a speculative buy on the thesis that Tebipenem HBr's regulatory path and clinical progress will re-rate the company from a micro-cap clinical-stage biotech to a takeout/approval candidate. The company carries limited debt, roughly $3.56M in cash on the books relative to a $133M market cap, and EV of $84.3M. This trade p…
Alto Ingredients is a small-cap specialty alcohols and renewable fuels producer trading at roughly $216M market cap. Recent bolt-on moves (a beverage-grade CO2 plant) and stronger cash-conversion potential argue the company is being priced for yesterday's cyclic ethanol margins, not the higher-margin, recurring CO2 and specialty-ingredient mix. Thi…
Ondas (ONDS) sits at the intersection of secure industrial connectivity and autonomous systems. Recent deals and a boosted 2026 revenue guide create a clear path to materially higher revenues, but valuation and execution risks remain. We lay out a long trade with concrete entry, target and stop, a 180-day horizon, and a balanced risk framework.
Meta has been reinvesting aggressively into AI infrastructure and Reality Labs while its Family of Apps continues to generate strong cash flow. Valuation sits at a reasonable premium for a company with $46.1B in free cash flow, a $1.74T market cap and double-digit returns on equity. This trade idea outlines an entry, stop and target for a long trad…
Prospect Capital (PSEC) is trading at about half of book value with an outsized cash yield and a recent string of corporate actions. This trade idea targets a NAV revaluation driven by clearer earnings cadence, ongoing portfolio de-risking, and shareholder-friendly activity. Enter at $2.80, stop at $2.30, target $3.60 over a 180 trading-day horizon…
Cannae trades below tangible book and well under past highs despite a portfolio of cash-generating assets and low leverage. Activist pressure and proxy advisory support make a mid-term rerating plausible. Plan: enter at $14.20, stop at $13.25, target $18.00 over the next 45 trading days.
Omega Healthcare Investors offers a 5.9% yield, steady cash flow from long-term healthcare properties, and valuation upside if the market re-rates REITs as interest-rate pressure eases. This trade plan lays out an actionable long trade with entry, stop and target, anchored to balance-sheet metrics and recent operating strength.
Microsoft's combination of durable cloud cash flows, strong profitability (ROE ~30%), low leverage, and accelerating AI-driven demand make the current pullback an attractive entry. Technical indicators show oversold conditions and compressed downside; we outline a mid-term (45 trading days) swing trade with disciplined risk management.
Mesoblast's real-world results for Ryoncil and a 60% quarterly sales ramp sharpen the commercial bull case. With gross Ryoncil sales of US$35.1M in the December quarter, an 84% survival signal in early pediatric SR-aGvHD real-world use, and a cleaner balance sheet via a new US$125M facility, Mesoblast (MESO) looks tradeable to the long side. This i…
UiPath (PATH) has lagged larger AI names but still offers an attractive risk/reward: durable SaaS fundamentals, an orchestration moat with Maestro, improving margins and strong cash flow. At roughly $13 the stock trades below its 52-week high and at a valuation that leaves upside if agentic AI adoption accelerates. This trade idea outlines a clear …
